40 filings
Page 2 of 2
8-K
q1rh5gw
8 Apr 22
Departure of Directors or Certain Officers
4:30pm
8-K
0p4s8
16 Mar 22
Prelude Therapeutics Reports Full Year 2021 Financial Results
8:05am
8-K
knoc2o2kccg652gs
9 Mar 22
Jane Huang, M.D., Joins Prelude Therapeutics as President and Chief Medical Officer
8:22am
8-K
73qo3y4cg8h
16 Feb 22
Regulation FD Disclosure
5:03pm
8-K
2yr5w
10 Jan 22
Regulation FD Disclosure
7:02am
8-K
x2qyymy8h1
3 Dec 21
Entry into a Material Definitive Agreement
9:00am
8-K
ak3ba3g
12 Nov 21
Prelude Therapeutics Announces Third Quarter 2021 Financial Results and Operations Update
7:57am
8-K
0growkltt3 oqpw
17 Sep 21
Departure of Directors or Certain Officers
8:32am
8-K
2kdurbwmh36
12 Aug 21
Prelude Therapeutics Announces Second Quarter 2021 Financial Results and Operations Update
10:41am
8-K
rgpqkte
19 Jul 21
Departure of Directors or Certain Officers
4:53pm
8-K
8utszzbr80
22 Jun 21
Submission of Matters to a Vote of Security Holders
4:02pm
8-K
qtyzbsxkn7 wcl
12 May 21
Regulation FD Disclosure
9:01am
8-K
h61b 4y1beeb
11 May 21
Prelude Therapeutics Announces First Quarter 2021 Financial Results and Operations Update
8:00am
8-K
y2v5qz1tbo5jns
17 Mar 21
Regulation FD Disclosure
9:02am
8-K
eqwjo8m6kpg ax
16 Mar 21
Prelude Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Operational Update
8:10am
8-K
nhzj7og
8 Mar 21
Departure of Directors or Certain Officers
4:09pm
8-K
fvhbtqx8cfv5583uf5m
28 Jan 21
Departure of Directors or Certain Officers
4:46pm
8-K
zswy5uo39y1jcukq
4 Jan 21
Results of Operations and Financial Condition
4:19pm
8-K
3lg nebtg56vaj
10 Nov 20
Prelude Therapeutics Announces Third Quarter 2020 Financial Results
7:37am
8-K
7vvvei 8be
4 Nov 20
Entry into a Material Definitive Agreement
4:09pm